Clinical Trial Update: Title XELOX FOR SALIVARY GLAND CANCERS [Phase 2]

View source ↗

Summary

Phase 2 study of the XELOX regimen (capecitabine plus oxaliplatin) for salivary gland cancers and head and neck cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Salivary Gland Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Head and Neck Cancer | Phase 2 | Status: TERMINATED